DELII: Ultralow‐dose nivolumab extended overall survival after prior systemic therapy

Cancer · Published 2026-07-15 · DOI 10.1002/cncr.70473

Authors (1)

Leah Lawrence

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Lawrence, L. (2026). DELII: Ultralow‐dose nivolumab extended overall survival after prior systemic therapy. Cancer. https://doi.org/10.1002/cncr.70473

Related articles

• New data inform decision‐making for breast cancer surgeries · Cancer · 2026 · Same journal
• Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis · Cancer · 2026 · Same journal
• Most older patients with advanced cancer prioritize QOL over extending survival · Cancer · 2026 · Same journal
• Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California · Cancer · 2026 · Same journal
• Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions · Cancer · 2026 · Same journal
• First‐line CDK4/6 inhibitors fail to improve overall survival in advanced breast cancer · Cancer · 2026 · Same journal
• HER2 ‐targeting zongertinib shows early activity in untreated advanced HER2 ‐mutant NSCLC · Cancer · 2026 · Same journal
• EXPRESSION OF CONCERN: Prolyl Hydroxylase‐2 (PHD2) Exerts Tumor‐Suppressive Activity in Pancreatic Cancer† · Cancer · 2026 · Same journal
• Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma · Cancer · 2026 · Same journal
• Sexual health behaviors and contraceptive practices among Canadian childhood, adolescent, and young adult cancer survivors and controls · Cancer · 2026 · Same journal